Sanofi

Japan Chooses Sanofi Pasteur for First Enhanced Inactivated Polio Vaccine

Friday, May 4, 2012 08:00 AM

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved Sanofi Pasteur’s, standalone Inactivated Poliovirus Vaccine (IPV) against acute flaccid poliomyelitis (Imovax Polio). Imovax Polio will be added to the country's public immunization program on September 1.

More... »

Rosenberg joins Esperion Therapeutics as CMO

Monday, April 9, 2012 02:56 PM

Esperion Therapeutics, a Plythmouth, Michigan-based company that discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases, has appointed Noah Rosenberg, MD, as its chief medical officer.

More... »

Sanofi, Regeneron share results for lipid-lowering PCSK9 antibody

Tuesday, March 27, 2012 06:34 AM

Sanofi and Regeneron Pharmaceuticals have reported promising data from two phase II trials with SAR236553/REGN727—an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).

More... »

ImmusanT names Patrick Griffin as chief medical officer, senior VP

Monday, March 19, 2012 12:37 PM

ImmusanT, a privately-held biotech based in Cambridge, Mass., has named Patrick H. Griffin, MD, as chief medical officer and senior vice president of development.

More... »

Sanofi acquires Pluromed, expands presence in biosurgery

Friday, March 16, 2012 04:12 PM

Sanofi has entered into an agreement with Pluromed to acquire the medical device company based in Woburn, Mass.

More... »

Sanofi to collaborate with the Center for Genomic Regulation

Friday, March 9, 2012 02:21 PM

The Center for Genomic Regulation (CRG), an international biomedical research institute of excellence supported by the Catalan government and the Spanish Ministry of Science and Innovation, has entered a research collaboration with Sanofi to share research programs using state-of-the-art experimental platforms and computational and bioinformatics approaches, in computational biology, medical genetics and epigenetics, with special emphasis in genetic and rare diseases.

More... »

FDA approves Sklice lotion for head lice

Friday, February 10, 2012 12:01 PM

The FDA has approved Sklice (ivermectin) lotion 0.5% for the topical treatment of head lice in patients 6 months of age and older, according to Sanofi.

More... »

Blueprint Medicines names Christoph Lengauer chief scientific officer

Friday, February 10, 2012 11:44 AM

Blueprint Medicines, a Cambridge, Mass.-based developer of personalized cancer therapies, has appointed Christoph Lengauer, Ph.D., chief scientific officer.

More... »

International collaboration to combat 10 neglected tropical diseases by 2020

Monday, January 30, 2012 03:49 PM

Thirteen pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organizations will join forces to eliminate or control 10 neglected tropical diseases (NTDs) by the end of the decade.

More... »

Genzyme announces FDA approval of Framingham manufacturing plant

Tuesday, January 24, 2012 02:52 PM

Cambridge, Mass.-based Genzyme, a Sanofi company, said the FDA has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme (agalsidase beta). This follows the previously announced approval by the EMA last week.

More... »